SCHEMBL6340397

SCHEMBL6340397

Nc1nc2c(Cc3cccc(F)c3)c[nH]c2c(=O)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PNP P00491 8/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6344896 0.86 PNP (0.75) PNP
SCHEMBL9073768 0.86 PNP (0.75) PNP
SCHEMBL6345393 0.86 PNP (1.00) PNP
SCHEMBL9050580 0.85 PNP (0.71) PNP
SCHEMBL6343588 0.85 PNP (1.00) PNP
SCHEMBL6345687 0.83 PNP (0.71) PNP
SCHEMBL6345179 0.80 PNP (0.81) PNP
Peldesine SCHEMBL61135 0.80 PNP (1.00) PNP
Peldesine SCHEMBL29364464 0.80 PNP (1.00) PNP
SCHEMBL6341905 0.80 PNP (1.00) PNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1995016689-A1 IMPROVED PROCESS FOR THE SYNTHESIS OF 2-AMINO-3,5-DIHYDRO-7-SUBSTITUTED-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES PARKE, DAVIS & COMPANY (US) 1995-06-22 WO claimed
US-6946554-B2 Process for the preparation of 9-deazaguanine derivatives BIOCRYST PHARMACEUTICALS, INC. (US) 2005-09-20 US disclosed
US-20040254181-A1 Process for the preparation of 9-deazaguanine derivatives BIOCRYST PHARMACEUTICALS, INC. 2004-12-16 US disclosed
EP-0970029-A1 PROCESS FOR THE PREPARATION OF 9-DEAZAGUANINE DERIVATIVES BIOCRYST PHARMACEUTICALS INC. (US) 2000-01-12 EP disclosed
US-5650511-A MULTISTAGE REACTION OF ALDEHYDE OR KETONE WITH NITRILE GROUP TO FORM ENAMINE, REACTION OF ENAMINE WITH BASE TO FORM PYRROLE, THEN REACTION BIOCRYST PHARMACEUTICALS, INC. (US) 1997-07-22 US disclosed
WO-1997021653-A1 PROCESS FOR THE PREPARATION OF 9-DEAZAGUANINE DERIVATIVES BIOCRYST PHARMACEUTICALS, INC. (US) 1997-06-19 WO disclosed
US-5565463-A PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 1996-10-15 US disclosed
WO-1995016689-A1 IMPROVED PROCESS FOR THE SYNTHESIS OF 2-AMINO-3,5-DIHYDRO-7-SUBSTITUTED-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES PARKE, DAVIS & COMPANY (US) 1995-06-22 WO disclosed
US-5386031-A Process for the synthesis of 2-amino-3,5-dihydro-7-substituted-4H-pyrrolo[3,]pyrimidin-4-ones WARNER-LAMBERT COMPANY (US) 1995-01-31 US disclosed
WO-1990010631-A1 9-SUBSTITUTED-8-UNSUBSTITUTED-9-DEAZAGUANINES BIOCRYST (US) 1990-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254181-A1 Process for the preparation of 9-deazaguanine derivatives ALKBH3, ALKBH2, ALKBH1 PNP 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.